EOSE
Eos Energy Enterprises, Inc.
There isn't enough reported data to score EOSE yet.
TGEN
Tecogen Inc.
TGEN lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
EOSE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
EOSE's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
TGEN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
TGEN's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
EOSE PE Valuation
EOSE has no meaningful PE right now: it lost money over the past year.
TGEN PE Valuation
TGEN has no meaningful PE right now: it lost money over the past year.
EOSE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect EOSE's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
TGEN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect TGEN's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
EOSE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$2.69 | +$0.85 |
| Q2 2023 | -$3.76 | -$1.00 |
| Q1 2023 | -$3.65 | -$0.86 |
| Q4 2022 | -$3.68 | -$1.32 |
| Q3 2022 | -$3.54 | +$5.19 |
EOSE has the stronger earnings trend. Trailing diluted EPS is down 224% for EOSE versus TGEN down 257%.
TGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.33 | -$0.12 |
| Q2 2026 | -$0.35 | -$0.17 |
| Q1 2026 | -$0.34 | -$0.16 |
| Q4 2025 | -$0.30 | -$0.11 |
| Q3 2025 | -$0.21 | +$0.01 |
| Q2 2025 | -$0.18 | +$0.02 |
| Q1 2025 | -$0.18 | -$0.01 |
| Q4 2024 | -$0.19 | $0.00 |
TGEN lost $0.33 per share over the past year, a bigger loss than the year before.
EOSE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $82.7M | +171% |
| Q2 2026 | $68.8M | +351% |
| Q1 2026 | $57M | +445% |
| Q4 2025 | $58M | +700% |
| Q3 2025 | $30.5M | +3473% |
| Q2 2025 | $15.2M | +1597% |
| Q1 2025 | $10.5M | +58% |
| Q4 2024 | $7.3M | +9.7% |
EOSE has the edge over TGEN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -96% | +105 points |
| Q2 2026 | -122% | +297 points |
| Q1 2026 | -139% | +367 points |
| Q4 2025 | -140% | +573 points |
| Q3 2025 | -201% | +6044 points |
| Q2 2025 | -419% | +2815 points |
| Q1 2025 | -506% | +117 points |
| Q4 2024 | -713% | -74 points |
EOSE's operating margin was −96% last quarter, up 105 points from the same quarter a year ago, near the top of its range since 2019.
TGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.9M | +9.6% |
| Q2 2026 | $5.7M | -21% |
| Q1 2026 | $6.3M | -13% |
| Q4 2025 | $5.3M | -12% |
| Q3 2025 | $7.2M | +28% |
| Q2 2025 | $7.3M | +54% |
| Q1 2025 | $7.3M | +18% |
| Q4 2024 | $6.1M | +3% |
TGEN's revenue is down over the past year, though its latest quarter was up: $8M last quarter, up 9.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -20% | +9.4 points |
| Q2 2026 | -37% | -18 points |
| Q1 2026 | -34% | -26 points |
| Q4 2025 | -78% | -59 points |
| Q3 2025 | -29% | -14 points |
| Q2 2025 | -19% | +12 points |
| Q1 2025 | -8.2% | +8.8 points |
| Q4 2024 | -19% | +12 points |
TGEN has the edge over EOSE on profitability, with a higher operating margin.
EOSE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$105.1M | -$22.4M |
| Q2 2026 | -$107.4M | -$34.3M |
| Q1 2026 | -$154.8M | -$121M |
| Q4 2025 | -$75.2M | -$19.5M |
| Q3 2025 | -$82.7M | -$28.5M |
| Q2 2025 | -$73.2M | -$40.6M |
| Q1 2025 | -$33.8M | +$10.7M |
| Q4 2024 | -$55.8M | -$10.2M |
EOSE has burned cash in almost every quarter: −$443M over the past year, against −$246M the year before.
TGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.4M | +$2.2M |
| Q2 2026 | -$2.4M | +$321.5K |
| Q1 2026 | -$3.2M | -$1.8M |
| Q4 2025 | -$2.6M | -165% |
| Q3 2025 | -$3.6M | -$3.1M |
| Q2 2025 | -$2.7M | -$2.1M |
| Q1 2025 | -$1.3M | -1011% |
| Q4 2024 | $4M | +2126% |
TGEN has the edge over EOSE on cash flow, with more consistent year-over-year improvement.
EOSE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +63% | +213M shares |
| 1 year | +161% | +341M shares |
| 3 years | +888% | +497M shares |
EOSE has 553M diluted shares, up 161% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
TGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +184K shares |
| 1 year | +4.7% | +1.4M shares |
| 3 years | +21% | +5.3M shares |
| 5 years | +20% | +5M shares |
| Available history | +22% | +5.3M shares |
TGEN has the edge over EOSE on shareholder dilution, with a more favorable share count trend.
EOSE Net Leverage
EOSE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
TGEN Net Leverage
TGEN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
EOSE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.5 | Neutral |
| Stochastic | 7.4 | Oversold |
EOSE's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
TGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.6 | Neutral |
| Stochastic | 12.3 | Oversold |
TGEN's weekly RSI is 38 (neutral) and its Stochastic is 12 (oversold).
EOSE PE vs Industrials Sector
EOSE has no meaningful PE right now: it lost money over the past year.
TGEN PE vs Industrials Sector
| Metric | TGEN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 24x | — |
TGEN has no meaningful PE right now: it lost money over the past year.
EOSE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.24 | 19% below |
| 20 week MA | $3.28 | 45% below |
| 50 week MA | $7.01 | 74% below |
| 100 week MA | $7.10 | 75% below |
| 200 week MA | $4.53 | 60% below |
EOSE is in a downtrend: it's below all five of its weekly moving averages, and 60% below its 200-week average.
TGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.28 | 2.6% below |
| 20 week MA | $3.02 | 26% below |
| 50 week MA | $3.94 | 44% below |
| 100 week MA | $4.64 | 52% below |
| 200 week MA | $2.78 | 20% below |
TGEN is in a downtrend: it's below all five of its weekly moving averages, and 20% below its 200-week average.
EOSE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.72 | $19.2 | +98% |
| 2021 | $19.2 | $8.57 | -55% |
| 2022 | $8.57 | $1.08 | -87% |
| 2023 | $1.08 | $1.09 | +0.9% |
| 2024 | $1.09 | $5.17 | +374% |
| 2025 | $5.17 | $11.9 | +129% |
| 2026 YTD | $11.9 | $1.81 | -85% |
EOSE's yearly returns have swung widely, from +374% in 2024 to −87% in 2022. It's down 85% so far in 2026.
TGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.26 | $1.17 | -48% |
| 2021 | $1.17 | $1.16 | -0.9% |
| 2022 | $1.16 | $1.21 | +4.3% |
| 2023 | $1.21 | $0.81 | -33% |
| 2024 | $0.81 | $1.45 | +79% |
| 2025 | $1.45 | $5.18 | +257% |
| 2026 YTD | $5.18 | $2.22 | -57% |
TGEN has the edge over EOSE on returns for 2026, with the stronger performance.